AXSM News and Press, Axsome Therapeutics Inc. From 01/01/24

2024-01-01 06:50:00 ET No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen. Three Fool.com contributors have done just that. Here's why they think that Axsome Therapeutics (NASDAQ: AXSM) ...

2023-12-27 12:41:31 ET Summary Harmony Biosciences Holdings, Inc. is facing challenges including a failed Phase 3 study, doubts about its patent estate, and competition from rivals. The company's drug, Wakix, has been successful in generating revenue, but its monopoly is being cha...

2023-12-24 09:28:20 ET Summary Axsome Therapeutics has consistently beaten revenue estimates since the approval of Auvelity, indicating better-than-expected performance. While the company's expenses, particularly in commercial activities for Sunosi and Auvelity, have been high, le...

2023-12-13 14:55:30 ET More on Axsome Therapeutics Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade) Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Call Transcript Axs...

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a patient’s interest-acti...

2023-12-10 06:56:00 ET What are some unstoppable stocks to buy right now? Three Fool.com contributors think they've found three stocks that qualify -- and they're all in the healthcare sector. Here's why they picked Axsome Therapeutics (NASDAQ: AXSM) , Eli Lilly (NYSE: LLY) ...

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m. ...

2023-11-27 10:41:32 ET Summary Axsome Therapeutics reports robust Q3 earnings with record revenue of $57.8 million, driven by sales of flagship product Auvelity. The company plans to expand its sales force to deepen market penetration and reach a broader base of prescribers and pa...

2023-11-23 15:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8 a.m. - 1...